LigoCyte forges deal with Biogen Idec

LigoCyte Pharmaceuticals has forged a deal to co-develop anti-inflammatory drugs with Biogen Idec. Researchers from both companies will be developing drugs that target CD103, a unique alphaE-beta7 integrin that has been implicated in the activation, homing and retention of lymphocytes that mediate inflammatory diseases affecting mucosal regions of the intestine, skin, and lungs. Those diseases can include respiratory, gastrointestinal, and autoimmune disorders. LigoCyte stands to earn a schedule of milestones for successful programs and retains co-development and co-promotion rights on new drugs as well.

- check out the release
- here's the report from the Triangle Business Journal

Related Articles:
Biogen Idec's CEO nets bonus despite bad year. Report
Biogen Idec considering sale of cancer drug. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.